# BiPSEE

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bipsee

- Industry: Healthcare IT
- Headquarters: Tokyo, Japan
- Website: https://bipsee.co.jp
- Latest round: Series A (Aug 17, 2026)
- Investors on record: 4

## About

Founded in 2017 and based in Tokyo, Japan, BiPSEE Inc., a healthcare technology firm that specializes in the development of VR digital therapeutics (VRx), AI-driven mental health solutions, and medical XR technologies. The company aims to produce evidence-based treatments for mental health disorders, including a VR-based digital therapeutic for depression, which is presently in the stages of clinical development and regulatory approval in Japan. As of August 2026, the CEO of the company is Masayo Matsumura. In August 2026, BiPSEE Inc. raised an undisclosed amount in series A funding from JIC Venture Growth Investments and Kyoto University Innovation Capital.

BiPSEE specializes in advanced technological solutions aimed at enhancing operational efficiencies across various sectors. The company's core offerings include a suite of software products designed to streamline data management and improve decision-making processes for businesses. These products address specific pain points such as data integration, analytics, and real-time reporting, essential in today’s fast-paced business environment. BiPSEE serves a diverse clientele, including enterprises in manufacturing, finance, and healthcare, primarily targeting markets in North America and Europe, focusing on providing reliable and scalable solutions for optimal operational efficiency. BiPSEE generates revenue through creating and offering VR digital therapeutics, AI-driven mental health care solutions, and medical XR technologies for healthcare providers, organizations, and various healthcare-related partners. The company is progressing in the clinical development and regulatory approval of its VR-based digital therapeutic aimed at treating depression, which could facilitate future commercialization prospects.

The company plans to use the August 2026 funding for clinical trial execution, regulatory approval preparation, product development, and quality assurance enhancement for VR-based depression treatment.

## Funding rounds

- Series A, Aug 17, 2026 — Kyoto University Innovation Capital, JIC Venture Growth Investments
- Series A, Jun 26, 2025 — Scrum Ventures, Beyond Next Ventures, Kyoto University Innovation Capital

## Investors

- Scrum Ventures (https://capitalatlas.ai/funds/scrum-ventures) — Series A
- Beyond Next Ventures (https://capitalatlas.ai/funds/beyond-next-ventures) — Series A
- Kyoto University Innovation Capital (https://capitalatlas.ai/funds/kyoto-university-innovation-capital) — Series A
- JIC Venture Growth Investments (https://capitalatlas.ai/funds/jic-venture-growth-investments) — Series A